Phantom Motor Execution via Myoelectric Pattern Recognition, Augmented Reality, and Serious Gaming as a treatment of Phantom Limb Pai
- Conditions
- Fantoompijn na een amputatiePhantom Limb Pain
- Registration Number
- NL-OMON48734
- Lead Sponsor
- Chalmers Technical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 25
Subject must be older than 18 years, must have an acquired amputation of upper or lower limb.
• If the subjects are under pharmacological treatments, there must be no variations on the medicament dosages for at least one month (steady consumption).
• The last session of previous treatments must be at least 3 months old.
• Any pain reduction potentially attributed to previous PLP treatments must be at least 3 months old.
• Subjects must have control over at least a portion of biceps and triceps muscles for upper limb amputations, and quadriceps and hamstrings for the lower limb amputations.
• The subject has signed a written informed consent.
• The subject must be in a stable prosthetic situation (i.e. satisfied with the fitting of the prosthesis) or being a nonuser.
• At least six months should be passed since the amputation: acute PLP cases should not be included in the study.
• The patient subject should not have a significant cognitive impairment that prevents the patient from following instructions.
• Subjects with abundant soft tissue on their stump will not be automatically excluded, however, an evaluation in the system is required to analyze if sufficient electromyography signals can be recorded.
• The subject should not have any condition associated with risk of poor protocol compliance.
• The subject should not have any other condition or symptoms preventing the patient from entering the study, according to the investigator*s judgment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary: Changes in PLP will be measured in terms of differences between the<br /><br>Pain Rating Index registered at the beginning (1st session) and at the end of<br /><br>the treatment (15th session).</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary: The effects of the treatment will be measured as changes in the PDI<br /><br>measures at the beginning (1st session) and at the end of the treatment (15th<br /><br>session).</p><br>